is noom glp 1 worth it expands its GLP-1 range with 'microdose' package Noom Enters Longevity Health Space

Compared to Novo Nordisks A/S (NYSE: NVO) Rybelsus, orforglipron appears to have multiple advantages

doi: 10.1152/physrev.00025.2016

Oral semaglutide ($249/month) and oral tirzepatide ($279/month) suit patients who prefer non-injection options, though injectable versions deliver faster symptom relief and superior weight loss in most trials

These drugs aim to improve the oral bioavailability of peptides or use oral small molecules to further enhance patient adherence

Moreover, among patients with T2DM and established cardiovascular disease, some trials reported the additional benefit of a lower rate of major adverse cardiac events (MACE) in patients treated with SGLT2-i (7, 10)

Department of Veterans Affairs